Using Mastermind to automate the design of a pan-hematopoietic malignancy gene panel, Dr. Mark Kiel generated a set of biomarker candidates that includes 314 genes associated with leukemia and 311 genes associated with lymphoma. Each of these candidate biomarker genes were manually annotated based on likely mechanism of pathogenesis including mutation, expression, copy number and … Continue reading Evidence-Based Pan-Hematopoietic NGS Gene Panel
Tag: Evidence-Based NGS Panel Design
This blog post has moved to a new home! Click here to view this post on the new Genomenon Blog.
Mining Genomic Literature to Develop Evidence-Based NGS Panels Corporate Workshop at AMP 2017 Wednesday, November 15, 2017, 4:00 PM, Room 255D Dr. Victor Weigman, Director, Translational Genomics at Q2 Solutions Dr. Ryan Schmidt, Molecular Genetic Pathology Fellow, Harvard Medical School Dr. Mark Kiel, CSO and Founder, Genomenon Clinicians and researchers face a daunting challenge when … Continue reading AMP 2017 Workshop: Developing Evidence-Based NGS Gene Panels